Handa Pharma's multiple sclerosis drug clears US FDA's new drug review and is approved for marketing

Handa Pharmaceuticals's subsidiary Handa Neuroscience's new 505(b)(2) drug Tascenso ODT, 0.5mg, for the treatment of multiple sclerosis, has received FDA's final approval.